This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Prognosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The prognoses for patients with two common causes of the nephrotic syndrome are as follows:

  • minimal change disease (MCD):
    • a third have just one episode
    • a third have infrequent relapses
    • a third have frequent relapses throughout childhood which abate during adulthood; life expectancy is normal

  • focal segmental glomerulosclerosis:
    • a third remit after a prolonged course
    • a third have continuing haematuria and proteinuria but have normal renal function
    • a third progress to end stage renal failure

In adults:

  • untreated MCD is associated with a risk of mortality due to infection and thromboembolism
  • limited data suggest that the rate of spontaneous early remission (eg, within a few months) in adults is approximately 5 to 10 percent
  • a substantial proportion of untreated patients eventually undergo remission after a prolonged period
    • only available randomized controlled trial that, in 1970, compared prednisone versus no specific therapy and included 31 patients with MCD
      • remission of proteinuria to less than 1 g/day in the control group occurred in 50 percent by 18 months and approximately 70 percent at three years
      • suuggests that the chief benefit of glucocorticoid is to induce and maintain remission until the poorly understood process responsible for MCD abates.

Reference:

 


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.